{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Trident Texofab Ltd
Is Trident Texofab technically bullish or bearish?
As of December 3, 2025, the trend is mildly bullish, supported by daily moving averages and Bollinger Bands, though caution is advised due to a mildly bearish weekly MACD and bearish monthly RSI.
Trident Texofab Technical Momentum Shifts Amid Mixed Market Signals
Trident Texofab, a key player in the Garments & Apparels sector, has experienced notable shifts in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition in price trends and technical indicators, signalling a nuanced outlook for investors amid fluctuating market conditions.
How has been the historical performance of Trident Texofab?
Trident Texofab has shown steady growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with profits also rising significantly. However, cash flow from operating activities turned negative in Mar'25, indicating challenges in cash management despite overall financial growth.
Is Trident Texofab overvalued or undervalued?
As of November 18, 2025, Trident Texofab is considered very expensive and overvalued, with a PE ratio of 174.34 and other high valuation metrics, indicating that investors may be overpaying despite the stock's recent strong performance.
Is Trident Texofab overvalued or undervalued?
As of November 17, 2025, Trident Texofab is considered overvalued with a valuation grade of expensive, reflected by its high PE ratio of 170.80 and other elevated metrics compared to industry peers.
Why is Trident Texofab falling/rising?
As of 17-Nov, Trident Texofab Ltd's stock price is Rs 337.50, up 2.9% today and showing strong long-term growth with a 100.65% year-to-date increase. However, a significant drop in delivery volume raises concerns about ongoing investor interest despite recent gains.
Trident Texofab Shows Strong Financial Performance Amid High Debt Concerns
Trident Texofab, a microcap in the Garments & Apparels sector, has seen a recent evaluation adjustment amid strong financial performance over the past four quarters. The company has achieved significant market returns but faces challenges with a high debt-to-equity ratio and limited profitability relative to shareholders' funds.
How has been the historical performance of Trident Texofab?
Trident Texofab has shown steady growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, despite fluctuations in costs and a decline in operating profit margins. Profit after tax rose to 2.51 Cr in Mar'25, but cash flow from operations turned negative at -13.00 Cr.
Trident Texofab Q2 FY26: Strong Profit Growth Masks Valuation Concerns
Trident Texofab Ltd., a micro-cap player in the garments and apparels sector, reported a robust quarter in Q2 FY26, with net profit surging to ₹1.13 crores—marking an 11% sequential improvement and a 13% year-on-year gain. However, the company's stock, currently trading at ₹328.00 with a market capitalisation of ₹502.00 crores, faces significant headwinds from its stretched valuation metrics and deteriorating operating cash flows. Despite delivering impressive revenue growth of 15.80% year-on-year, the company's premium P/E ratio of 166x and elevated debt levels raise critical questions about sustainability.
How has been the historical performance of Trident Texofab?
Trident Texofab has shown steady growth in net sales and profits from Mar'21 to Mar'25, with net sales increasing from 49.93 Cr to 122.06 Cr, although it faced fluctuations in costs and a negative cash flow of -13.00 Cr in Mar'25. Total liabilities and assets both rose to 100.58 Cr during this period, indicating overall growth despite challenges.
How has been the historical performance of Trident Texofab?
Trident Texofab has shown steady growth in net sales, reaching 122.06 Cr in Mar'25, with profits before and after tax increasing to 2.58 Cr and 2.51 Cr, respectively. Despite negative cash flow from operating activities, the company improved its financial health with reduced debt and increased equity capital and reserves.
How has been the historical performance of Trident Texofab?
Trident Texofab has shown consistent growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with total assets rising to 100.58 Cr and earnings per share improving to 1.85. The company also reduced its total debt, indicating enhanced financial health and profitability.
Trident Texofab Ltd Faces Significant Selling Pressure with 5% Decline Amid Ongoing Losses
Trident Texofab Ltd is experiencing significant selling pressure, marked by a notable decline in its share price over the past three days. The stock has fallen 11.44% in the past week and 15.10% in the last month, despite a strong annual performance. Current trends indicate a shift in market sentiment.
Trident Texofab Adjusts Evaluation Amid Strong Returns and Long-Term Challenges
Trident Texofab, a microcap in the Garments & Apparels sector, has recently adjusted its evaluation amid a shift in market trends. The company reported a 198.32% return over the past year and a 24.20% net sales growth, despite facing challenges in long-term financial strength.
Why is Trident Texofab falling/rising?
As of 10-Nov, Trident Texofab Ltd's stock price is at 319.05, down 3.39% and has underperformed with an 8.37% decline over the last two days and 9.91% over the past week. Despite strong year-to-date growth of 89.68%, the stock is facing short-term challenges compared to the broader market.
Trident Texofab Ltd Faces Selling Pressure with 5.00% Decline Amidst 11.41% Weekly Loss
Trident Texofab Ltd is experiencing notable selling pressure, with the stock declining 5.00% in today's trading and 8.46% over the past two days. Despite a strong annual performance, recent trends show underperformance compared to the broader market, contributing to increased selling activity.
When is the next results date for Trident Texofab?
The next results date for Trident Texofab is 13 November 2025.
Trident Texofab Ltd Faces Selling Pressure with 2.29% Price Decline Amid Market Losses
Trident Texofab Ltd is experiencing notable selling pressure, with a 2.29% decline in one-day performance, continuing a downward trend over the past week. The stock has also underperformed its sector and is currently below several moving averages, raising concerns about market sentiment despite strong long-term gains.
Trident Texofab Ltd Faces Heavy Selling Pressure, Stock Declines 5.00% Amid Cumulative Losses
Trident Texofab Ltd is experiencing notable selling pressure, with the stock declining significantly over recent days. Despite a strong annual performance, the stock has faced consecutive losses, diverging from the broader market trends. Current trading indicators suggest a potential shift in momentum amid this downturn.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
